MCM
DSGN icon

MAI Capital Management’s Design Therapeutics DSGN Stock Holding History

MAI Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8
Closed -$86 – 2772
2026
Q1 		$86 Buy
+8
New +$81 ﹤0.01% 4785

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MAI Capital Management's DSGN Position: Q2 2026 in Review

MAI Capital Management sold out of Design Therapeutics (DSGN) in Q2 2026, closing a stake of 8 shares — an estimated $86 sold.

MAI Capital Management first reported a position in DSGN in Q1 2026 and held it in 1 quarter. The position peaked at $86 in Q1 2026. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • MAI Capital Management reported no remaining Design Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 8 Design Therapeutics shares in Q2 2026, an estimated $86.
  • MAI Capital Management first reported a position in Design Therapeutics in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's Design Therapeutics position peaked at $86 in Q1 2026.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.